Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14868592 | 0.77 | L3MBTL1 (0.33) | L3MBTL1 | |
| SCHEMBL14868571 | 0.75 | ALOX5 (0.40) | CA1CA2ALOX5 | |
| SCHEMBL24433741 | 0.75 | CA1 (0.32) | CA1CA2 | |
| SCHEMBL24433710 | 0.73 | TSHR (0.33) | CA1CA2 | |
| SCHEMBL14868316 | 0.73 | GRIN2D (0.45) | CA1CA2L3MBTL1 | |
| SCHEMBL26268449 | 0.72 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL14868419 | 0.72 | ERCC1 (0.48) | CA1CA2 | |
| SCHEMBL14868623 | 0.72 | ALOX5 (0.42) | L3MBTL1ALOX5 | |
| SCHEMBL15100672 | 0.71 | TSHR (0.51) | — | |
| SCHEMBL14868607 | 0.71 | ALOX5 (0.31) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | SLC5A2, SLC5A1, GPR119 | CA1 3461/4885CA2 1106/4885L3MBTL1 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.